BiomX Inc. (PHGE)
| Market Cap | 11.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.89M |
| Shares Out | 35.96M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,841 |
| Open | 0.302 |
| Previous Close | 0.320 |
| Day's Range | 0.302 - 0.322 |
| 52-Week Range | 0.132 - 2.140 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 8.16 (+2,437.31%) |
| Earnings Date | May 9, 2023 |
About PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PHGE stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 2,437.31% from the latest price.
News
Why Is BiomX (PHGE) Stock Up 8% Today?
BiomX (NYSEMKT: PHGE) stock is rising on Wednesday following the release of the company's earnings report for the fourth quarter of 2022. Starting off that earnings report is the company's net loss o...
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”)
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...
Why Is BiomX (PHGE) Stock Down 11% Today?
BiomX (NYSEMKT: PHGE) stock is taking a beating on Wednesday after the clinical-stage microbiome company revealed details of a new private placement. According to a news release, BiomX has entered in...
BiomX Announces $7.5 Million Private Placement
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...
BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
BX004 therapy safe and well - tolerated across all patients and dose levels
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage ther...
BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update
Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023
BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage ther...
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target...
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that targe...
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
Why BiomX Shares Are Trading Higher Today?
BiomX Inc (NYSE: PHGE) has announced a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD). BiomX is a clinical-stage microbiome company advancing ...
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or “Company”) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflam...
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
BRANFORD, Conn. and NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage t...
BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed
BiomX Inc (NYSE: PHGE) announced a corporate restructuring plan to focus its resources and extend the cash runway. The company had $55.7 million in cash, cash equivalents, short-term deposits, and a $...
BiomX Announces Corporate Restructuring
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX Announces Publication in the Journal, Bioinformatics
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage the...
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022
NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target...